Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

Robert Andrew Berman net worth and biography

Robert Berman Biography and Net Worth

CEO of enVVeno Medical

Robert Berman has served as our Chief Executive Officer and a member of our Board of Directors since April of 2018, during which time he has successfully transitioned the company from being a small private company focused on cardiac care, to a publicly traded entity focused on venous disease. Mr. Berman has over 25 years of experience in a broad variety of areas including healthcare, finance, acquisitions, marketing, compliance, turnarounds, and the development and licensing of emerging technologies. From September 2012 until July 2017, he served as the President, Chief Executive Officer, and a member of the Board of Directors of ITUS Corporation (now called Anixa Biosciences), which at the time he joined the company was a developer of flat panel display technologies, and under his leadership became a Nasdaq listed cancer therapeutics company. From 2000 to March 2007, Mr. Berman was the Chief Operating Officer and General Counsel of Acacia Research Corporation, where he successfully transitioned the company from being an incubator of internet startups into the preeminent, publicly traded company for licensing and enforcing patented technologies with a market cap exceeding $2 billion. Mr. Berman started his career at the law firm of Blank Rome. Mr. Berman has a B.S. in Entrepreneurial Management from the Wharton School of the University of Pennsylvania and holds a J.D. from the Northwestern University School of Law, where he is an adjunct faculty member.

What is Robert Andrew Berman's net worth?: The estimated net worth of Robert Andrew Berman is at least $1.08 million as of June 27th, 2022. Mr. Berman owns 210,236 shares of enVVeno Medical stock worth more than $1,080,613 as of April 25th. This net worth estimate does not reflect any other investments that Mr. Berman may own. Learn More about Robert Andrew Berman's net worth.
How do I contact Robert Andrew Berman?: The corporate mailing address for Mr. Berman and other enVVeno Medical executives is 70 DOPPLER, IRVINE CA, 92618. enVVeno Medical can also be reached via phone at (949) 261-2900. Learn More on Robert Andrew Berman's contact information.
Has Robert Andrew Berman been buying or selling shares of enVVeno Medical?: Robert Andrew Berman has not been actively trading shares of enVVeno Medical during the last quarter. Most recently, on Monday, June 27th, Robert Andrew Berman bought 2,500 shares of enVVeno Medical stock. The stock was acquired at an average cost of $3.80 per share, with a total value of $9,500.00. Following the completion of the transaction, the chief executive officer now directly owns 210,236 shares of the company's stock, valued at $798,896.80. Learn More on Robert Andrew Berman's trading history.
Who are enVVeno Medical's active insiders?: enVVeno Medical's insider roster includes Robert Berman (CEO), Francis Duhay (Director), Marc Glickman (SVP), Robert Gray (Director), and Matthew Jenusaitis (Director). Learn More on enVVeno Medical's active insiders.
Are insiders buying or selling shares of enVVeno Medical?: In the last year, insiders at the sold shares 1 times. They sold a total of 8,334 shares worth more than $51,837.48. The most recent insider tranaction occured on March, 13th when CTO Hamed Alavi sold 8,334 shares worth more than $51,837.48. Insiders at enVVeno Medical own 17.0% of the company. Learn More about insider trades at enVVeno Medical.
Information on this page was last updated on 3/13/2024.

Robert Andrew Berman Insider Trading History at enVVeno Medical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/27/2022	Buy	2,500	$3.80	$9,500.00	210,236
11/19/2021	Buy	2,000	$7.43	$14,860.00
11/16/2021	Buy	2,000	$7.87	$15,740.00
5/18/2021	Buy	3,000	$5.47	$16,410.00	3,736
3/12/2019	Buy	21,740	$1.15	$25,001.00

Robert Andrew Berman Buying and Selling Activity at enVVeno Medical

enVVeno Medical Company Overview

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

Today's Range

Now: $5.14

$4.93

$5.28

50 Day Range

MA: $5.55

$4.62

$6.65

2 Week Range

Now: $5.14

$2.51

$6.97

Volume

67,175 shs

Average Volume

117,464 shs

Market Capitalization

$68.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

From Priority Gold | Ad